Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Liabilities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Total Liabilities data on record, last reported at $69.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 91.23% year-over-year to $69.2 million; the TTM value through Dec 2025 reached $69.2 million, up 91.23%, while the annual FY2025 figure was $69.2 million, 91.23% up from the prior year.
  • Total Liabilities reached $69.2 million in Q4 2025 per LCTX's latest filing, up from $68.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $69.2 million in Q4 2025 and bottomed at $11.2 million in Q2 2021.
  • Average Total Liabilities over 5 years is $40.7 million, with a median of $39.5 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 422.12% in 2022, then decreased 26.31% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $11.6 million in 2021, then skyrocketed by 345.05% to $51.7 million in 2022, then fell by 24.61% to $39.0 million in 2023, then dropped by 7.15% to $36.2 million in 2024, then soared by 91.23% to $69.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $69.2 million in Q4 2025, $68.8 million in Q3 2025, and $43.7 million in Q2 2025.